Fast Market Research

New Market Study Published: Cardio3 BioSciences SA - Product Pipeline Review - 2012

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 08/09/2012 -- Global Market Direct's pharmaceuticals report, "Cardio3 BioSciences SA - Product Pipeline Review - 2012" provides data on the Cardio3 BioSciences SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Cardio3 BioSciences SA's corporate website, SEC filings, investor presentations and featured press releases, both from Cardio3 BioSciences SA and industry-specific third party sources, put together by Global Markets Direct's team.


- Cardio3 BioSciences SA - Brief Cardio3 BioSciences SA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cardio3 BioSciences SA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cardio3 BioSciences SA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cardio3 BioSciences SA's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Cardio3 BioSciences SA's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cardio3 BioSciences SA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cardio3 BioSciences SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cardio3 BioSciences SA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cardio3 BioSciences SA and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Cardio3 BioSciences SA - Product Pipeline Review - H2 2011
- Heart Failure - Pipeline Review, H1 2012
- Transgene SA - Product Pipeline Review - 2012
- Ambit Biosciences Corporation - Product Pipeline Review - 2012
- Ardea Biosciences, Inc. - Product Pipeline Review - 2012
- NovImmune SA - Product Pipeline Review - 2012
- Neurocrine Biosciences, Inc. - Product Pipeline Review - 2012
- Evolva SA - Product Pipeline Review - 2012
- Hydra Biosciences, Inc. - Product Pipeline Review - 2012
- AC Immune SA - Product Pipeline Review - 2012